Nephros Reports 36% Revenue Growth and 405% Net Income Increase in Q2 2026

Nephros, Inc. reported a significant increase in financial performance for the second quarter and first half of 2026, as detailed in its latest 10-Q filing. For the three months ended June 30, 2026, the company generated total net revenues of $6.0 million, a 36% increase from $4.4 million in the same period of 2025. This growth was primarily driven by a rise in product revenues, which reached $5.7 million, up from $4.3 million year-over-year. The company also reported a net income of $1.2 million for the quarter, compared to $237,000 in the prior year, reflecting a 405% increase.

For the six months ended June 30, 2026, Nephros achieved total net revenues of $11.2 million, a 21% increase from $9.3 million in the first half of 2025. The company’s gross margin for the first half of 2026 was approximately 63%, slightly down from 64% in the previous year, attributed to increased product costs and a shift in revenue mix towards lower-margin service offerings. Operating income for the six-month period was $1.3 million, a 61% increase from $814,000 in 2025.

Operationally, Nephros has seen a rise in customer engagement, with a notable increase in accounts receivable, which rose to $4.1 million from $2.4 million, indicating higher sales volume. The company’s inventory also increased to $4.5 million from $3.2 million, reflecting efforts to support anticipated revenue growth. The total headcount increased, contributing to a 10% rise in selling, general, and administrative expenses, which reached $2.4 million for the quarter.

Strategically, Nephros has focused on expanding its product offerings and market reach. The company recently launched a new filtration solution capable of reducing Total PFAS, enhancing its portfolio to address emerging water quality concerns. Additionally, Nephros has benefited from a Supreme Court ruling that invalidated certain tariffs, resulting in a recognized tariff refund of approximately $624,000, which positively impacted its cost of goods sold.

Looking ahead, Nephros remains optimistic about its growth trajectory, emphasizing the importance of maintaining revenue growth and managing operational expenses. The company believes its existing cash balances and projected cash flows will be sufficient to fund operations for at least the next 12 months. However, it acknowledges potential challenges, including market acceptance of its products and the impact of competitive conditions on demand.